3 Most Common Premarket (Postmarket?) Review Issues FDA Sees

51:44 | Jun 25th

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re highlighting comments made by FDA representatives at an event about the most common pr...Show More